Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, United States.
Antiviral Res. 2010 Jan;85(1):34-8. doi: 10.1016/j.antiviral.2009.10.006. Epub 2009 Oct 23.
The occasion of this 25th anniversary issue encouraged us to reminisce about the important history of the discovery of the dideoxynucleoside analogues for the treatment of HIV/AIDS and to chronicle our thoughts about a particular exciting and rewarding period of our scientific careers. Following the identification of the anti-HIV activity of zidovudine (AZT), we participated in the urgent quest to discover optimal treatments of HIV infection and AIDS. A number of previously synthesized nucleoside analogues were comparatively evaluated, and stavudine (D4T) emerged as a promising candidate for development. Following clinical evaluation, D4T became a mainstay of the initial antiretroviral combination therapy, prolonging and saving numerous lives. It has only recently been supplanted by better-tolerated treatments. This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, vol. 85, issue 1, 2010.
本期 25 周年特刊促使我们回忆起发现用于治疗 HIV/AIDS 的双脱氧核苷类似物的重要历史，并记录下我们对职业生涯中这一激动人心、收获颇丰的特殊时期的一些想法。在鉴定齐多夫定（AZT）的抗 HIV 活性后，我们参与了寻找 HIV 感染和艾滋病最佳治疗方法的紧急探索。对多种先前合成的核苷类似物进行了比较评估， stavudine（D4T）脱颖而出成为有开发前景的候选药物。经过临床评估，D4T 成为最初抗逆转录病毒联合疗法的基础，延长并挽救了众多生命。直到最近，它才被耐受性更好的治疗方法所取代。本文是抗病毒研究特刊的一部分，该特刊是为了纪念抗逆转录病毒药物发现和开发 25 周年，第 85 卷，第 1 期，2010 年。
